6 research outputs found
THSD7A Positivity Predicts Poor Survival and Is Linked to High FAK Expression and FGFR1-Wildtype in Female Patients with Squamous Cell Carcinoma of the Lung
Lung cancer is the leading cause of cancer-related deaths in the western world, with
squamous cell carcinoma being one of the most common histological subtypes. Prognostic and
predictive markers are still largely missing for squamous cell carcinoma of the lung (LSCC). Several
studies indicate that THSD7A might at least play a role in the prognosis of different tumors. FAK
seems to play an important role in lung cancer and is discussed as a potential therapeutic target. In
addition, there is evidence that FAK-dependent signaling pathways might be affected by THSD7A.
For that reason, we investigated the role of THSD7A as a potential tumor marker in LSCC and
whether THSD7A expression has an impact on the expression level of FAK. A total of 101 LSCCs were
analyzed by immunohistochemistry using tissue microarrays. THSD7A positivity was associated
with poor overall survival in female patients and showed a relation to high FAK expression in this
subgroup. To our knowledge, we are the first to report these correlations in lung cancer. The results
might be proof of the assumed activation of FAK-dependent signaling pathways by THSD7A and that
as a membrane-associated protein, THSD7A might serve as a putative therapeutic target in LSCC
THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
Prostate cancer is one of the most common malignancies, and there are a wide range of
treatment options after diagnosis. Most prostate cancers behave in an indolent manner. However, a
given sub-group has been shown to exhibit aggressive behavior; therefore, it is desirable to find novel
prognostic and predictive (molecular) markers. THSD7A expression is significantly associated with
unfavorable prognostic parameters in prostate cancer. FAK is overexpressed in several tumor types
and is believed to play a role in tumor progression and metastasis. Furthermore, there is evidence that
THSD7A might affect FAK-dependent signaling pathways. To examine whether THSD7A expression
has an impact on the expression level of FAK in its unphosphorylated form, a total of 461 prostate
cancers were analyzed by immunohistochemistry using tissue microarrays. THSD7A positivity and
low FAK expression were associated with adverse pathological features. THSD7A positivity was
significantly associated with high FAK expression. To our knowledge we are the first to show that
THSD7A positivity is associated with high FAK expression in prostate cancer. This might be proof
of the actual involvement of THSD7A in FAK-dependent signaling pathways. This is of special
importance because THSD7A might also serve as a putative therapeutic target in cancer therapy
SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis
Prostate cancer is one of the most common malignancies worldwide, showing a wide range
of clinical behaviors. Therefore, several treatment options arise out of the diagnosis “prostate cancer”.
For this reason, it is desirable to find novel prognostic and predictive markers. In former studies, we
showed that THSD7A expression is associated with unfavorable prognostic parameters in prostate
cancer and is linked to a high expression of focal adhesion kinase (FAK). Recently, scavenger receptor
class A member 5 (SCARA5) was reported to be the downstream gene of THSD7A in esophageal
squamous cell carcinoma. SCARA5 is believed to play an important role in the development and
progression of several different tumor types. Most studies describe SCARA5 as a tumor suppressor.
There is also evidence that SCARA 5 interacts with FAK. To examine the role of SCARA5 as a potential
biomarker in prostate cancer, a total of 461 prostate cancers were analyzed via immunohistochemistry
using tissue microarrays. Furthermore, we compared the expression level of SCARA5 with our
previously collected data on THSD7A and FAK. High SCARA5 expression was associated with
advanced tumor stage (p < 0.001), positive nodal status (p < 0.001) and high Gleason-score (p < 0.001).
At least, strongly SCARA5-positive cancers were associated with THSD7A-positivity. There was
no significant association between SCARA5 expression level and FAK expression level. To our
knowledge, we are the first to investigate the role of SCARA5 in prostate cancer and we demonstrated
that SCARA5 might be a potential biomarker in prostate cancer
THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer
Prostate cancer is one of the most common malignancies, and there are a wide range of treatment options after diagnosis. Most prostate cancers behave in an indolent manner. However, a given sub-group has been shown to exhibit aggressive behavior; therefore, it is desirable to find novel prognostic and predictive (molecular) markers. THSD7A expression is significantly associated with unfavorable prognostic parameters in prostate cancer. FAK is overexpressed in several tumor types and is believed to play a role in tumor progression and metastasis. Furthermore, there is evidence that THSD7A might affect FAK-dependent signaling pathways. To examine whether THSD7A expression has an impact on the expression level of FAK in its unphosphorylated form, a total of 461 prostate cancers were analyzed by immunohistochemistry using tissue microarrays. THSD7A positivity and low FAK expression were associated with adverse pathological features. THSD7A positivity was significantly associated with high FAK expression. To our knowledge we are the first to show that THSD7A positivity is associated with high FAK expression in prostate cancer. This might be proof of the actual involvement of THSD7A in FAK-dependent signaling pathways. This is of special importance because THSD7A might also serve as a putative therapeutic target in cancer therapy